Search results
Results from the WOW.Com Content Network
Interactions with other drugs, food and drink, and other factors may increase or decrease the effect of certain analgesics and alter their half-life. Because some listed analgesics are prodrugs or have active metabolites , individual variation in liver enzymes (e.g., CYP2D6 enzyme) may result in significantly altered effects.
Pioglitazone/metformin is indicated as an adjunct to diet and exercise: [medical citation needed] To improve glycemic control in patients with type 2 diabetes, or; For patients who are already treated with a separate combination of pioglitazone and metformin, For patients whose diabetes is not adequately controlled with metformin alone, or
Metformin, sold under the brand name Glucophage, among others, is the main first-line medication for the treatment of type 2 diabetes, [14] [15] [16] [17 ...
Alpha-glucosidase inhibitors (AGIs) are oral anti-diabetic drugs used for diabetes mellitus type 2 that work by preventing the digestion of carbohydrates (such as starch and table sugar). They are found in raw plants/herbs such as cinnamon and bacteria (containing the inhibitor acarbose ).
Vildagliptin/metformin is indicated in the treatment of type-2 diabetes mellitus: [4] [6] [7] it is indicated in the treatment of adults who are unable to achieve sufficient glycaemic control at their maximally tolerated dose of oral metformin alone or who are already treated with the combination of vildagliptin and metformin as separate tablets.
A drug combination chart designed for harm reduction by TripSit [1] Polysubstance use or multisubstance use is the use of combinations of psychoactive substances with both legal and illegal substances. This page lists polysubstance combinations that are entheogenic, recreational, or off-label indicated use of pharmaceuticals.
Empagliflozin/metformin was approved for use in the European Union in May 2015. [6] Empagliflozin/metformin was approved for use in the United States in August 2015. [9] [14] The extended release version was approved for use in the United States in December 2016. [15] [16] Empagliflozin/metformin was approved for use in Australia in May 2020. [2]
In the United States, sitagliptin/metformin is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes. [5] [6]In the European Union, sitagliptin/metformin is indicated as an adjunct to diet and exercise to improve glycemic control in people with type 2 diabetes; in combination with a sulfonylurea as an adjunct to diet and exercise "in people ...